Astron Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 1.00 M
as on 16-11-2024
- Company Age 35 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.21 Cr
as on 16-11-2024
- Satisfied Charges ₹ 2.50 M
as on 16-11-2024
- Revenue -4.54%
(FY 2023)
- Profit 1.20%
(FY 2023)
- Ebitda 23.92%
(FY 2023)
- Net Worth 23.54%
(FY 2023)
- Total Assets 24.88%
(FY 2023)
About Astron Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹2.21 Cr. The company has closed loans amounting to ₹2.50 M, as per Ministry of Corporate Affairs (MCA) records.
Pawan Goel, Satyam Goel, Anuj Goel, and One other member serve as directors at the Company.
- CIN/LLPIN
U74899DL1989PTC035303
- Company No.
035303
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Mar 1989
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Astron Pharmaceuticals Private Limited offer?
Astron Pharmaceuticals Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Anti Inflammatory Drugs.
Who are the key members and board of directors at Astron Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pawan Goel  | Director | 02-Mar-1989 | Current |
| Satyam Goel | Director | 25-Mar-2015 | Current |
| Anuj Goel | Director | 25-Mar-2015 | Current |
| Sangita Goel | Director | 02-Mar-1989 | Current |
Financial Performance of Astron Pharmaceuticals.
Astron Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 4.54% decrease. The company also saw a slight improvement in profitability, with a 1.2% increase in profit. The company's net worth Soared by an impressive increase of 23.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Astron Pharmaceuticals?
In 2023, Astron Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Astron Plastochem Private LimitedActive 2 years 10 monthsPawan Goel and Sangita Goel are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 17 May 2024 | ₹2.00 Cr | Open |
Others Creation Date: 10 May 2022 | ₹2.00 M | Open |
Canara Bank Creation Date: 07 Nov 2020 | ₹0.10 M | Open |
How Many Employees Work at Astron Pharmaceuticals?
Unlock and access historical data on people associated with Astron Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Astron Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Astron Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
